Dermatica Laboratories Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 5 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 72.30%
- Profit Growth 86.00%
- Ebitda 84.99%
- Net Worth 174.10%
- Total Assets 98.82%
About Dermatica Laboratories
Dermatica Laboratories Private Limited (DLPL) is a Private Limited Indian Non-Government Company incorporated in India on 19 August 2019 (Five years and six months 6 days old ). Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Deepali Chavan and Piyush Padmawar serve as directors at the Company.
Company Details
- Location
Thane, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24299MH2019PTC329405
- Company No.
329405
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Aug 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Dermatica Laboratories?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Deepali Chavan  | Director | 19-Aug-2019 | Current |
| Piyush Padmawar | Director | 18-May-2021 | Current |
Financial Performance of Dermatica Laboratories.
Dermatica Laboratories Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 72.3% increase. The company also saw a substantial improvement in profitability, with a 86% increase in profit. The company's net worth Soared by an impressive increase of 174.1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dermatica Laboratories?
Unlock access to Dermatica Laboratories's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dermatica Laboratories?
Dermatica Laboratories has a workforce of 23 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dermatica Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dermatica Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
